In fact, bevacizumab was shown to upregulate ANGPT2, and blockade of both VEGF and ANGPT2 extended survival, decreased vascular permeability by potentially reducing vasogenic cerebral edema, and favored antitumor immunity by enhancing tumor infiltrating lymphocytes and decreasing tumor-associated macrophages (30). The gene discussed is VEGFA; the disease is neoplasm.